知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

71 条记录 (耗时 0.041 秒)

    Cytotoxic therapy
    3.
    发明申请
    Cytotoxic therapy 审中-公开
    细胞毒性治疗

    公开(公告)号：US20070148088A1

    公开(公告)日：2007-06-28

    申请号：US11529803

    申请日：2006-09-29

    申请人： David Goldenberg

    发明人： David Goldenberg

    IPC分类号： A61K51/00 ,  A61K38/18

    CPC分类号： A61K51/1063 ,  A61K39/44 ,  A61K47/6813 ,  A61K47/6849 ,  A61K47/6863 ,  A61K47/6865 ,  A61K51/1039 ,  A61K51/1066 ,  A61K2121/00 ,  A61K38/00 ,  A61K2300/00

    摘要： Anticancer, antimicrobial and autoimmune disease, and anti-organ rejection therapy using cytotoxic agents is improved using cytokines to prevent, mitigate or reverse adverse radiation-induced or drug-induced toxicity, especially to hematopoietic cells. Cytotoxic agents can include radioisotopes, drugs, toxins and even unconjugated cytotoxic antibodies. A preferred cytokine is IL-1. Higher doses of cytotoxic agents can be administered and tolerated by the patient and dose-limiting marrow toxicity can be prevented, palliated or reversed using adjunct cytokine therapy. Polyspecific immunoconjugates and antibody composites that bind a multidrug transporter protein and an antigen associated with a tumor or infectious agent are used to overcome the multidrug resistant phenotype. These immunoconjugates and composites also can be used diagnostically to determine whether the failure of traditional chemotherapy is due to the presence of multidrug resistant tumor cells, multidrug resistant HIV-infected cells or multidrug resistant infectious agents.

    摘要翻译： 使用细胞因子来预防，减轻或逆转不利的放射诱导或药物诱导的毒性，特别是造血细胞，改善抗癌，抗微生物和自身免疫性疾病以及使用细胞毒性剂的抗器官排斥治疗。 细胞毒剂可以包括放射性同位素，药物，毒素，甚至是非共轭的细胞毒性抗体。 优选的细胞因子是IL-1。 更高剂量的细胞毒性剂可以由患者施用和耐受，并且可以使用辅助细胞因子治疗来阻止剂量限制性骨髓毒性，缓解或逆转。 结合多药转运蛋白和与肿瘤或感染因子相关的抗原的多特异性免疫偶联物和抗体复合物被用于克服多药耐药表型。 这些免疫缀合物和复合物也可用于诊断，以确定传统化学疗法的失败是否由于存在多药耐药性肿瘤细胞，多药耐药HIV感染细胞或多重耐药感染剂。

    METHOD OF DETERMINING CYTOKINE DOSAGE FOR MYELOSUPPRESSIVE STATE
    6.
    发明申请
    METHOD OF DETERMINING CYTOKINE DOSAGE FOR MYELOSUPPRESSIVE STATE 有权
    确定用于免疫抑制状态的细胞因子剂量的方法

    公开(公告)号：US20060193770A1

    公开(公告)日：2006-08-31

    申请号：US10173550

    申请日：2002-06-14

    申请人： Rosalyn Blumenthal ,  David Goldenberg

    发明人： Rosalyn Blumenthal ,  David Goldenberg

    IPC分类号： A61K51/00 ,  A61K38/19 ,  G01N33/53

    CPC分类号： G01N33/6863 ,  G01N33/57488 ,  G01N2333/475 ,  G01N2800/24

    摘要： The invention provides kits and methods for evaluating the myelosuppressive state of a patient. These methods and kits provide a useful adjunct for cytotoxic and myelosuppressive therapies. By establishing threshold levels of certain cytokines as a surrogate for myelosuppression, treatment protocols can be optimized to reduce myelotoxicity, while maximizing effective dose.

    摘要翻译： 本发明提供了用于评估患者骨髓抑制状态的试剂盒和方法。 这些方法和试剂盒为细胞毒性和骨髓抑制治疗提供了有用的辅助物质。 通过建立某些细胞因子的阈值水平作为骨髓抑制的替代物，治疗方案可以优化，以减少骨髓毒性，同时最大化有效剂量。

    Detection and treatment of infections with immunoconjugates
    10.
    发明授权
    Detection and treatment of infections with immunoconjugates 失效

    公开(公告)号：US06548275B2

    公开(公告)日：2003-04-15

    申请号：US10125342

    申请日：2002-04-19

    申请人： M. David Goldenberg

    发明人： M. David Goldenberg

    IPC分类号： C12P2104

    CPC分类号： A61K51/1018 ,  A61K47/68 ,  A61K51/10 ,  A61K2123/00

    摘要： A method of targeting a diagnostic or therapeutic agent to a focus of infection comprises injecting a patient infected with a pathogen parenterally with an antibody conjugate which specifically binds to an accessible epitope of the pathogen or of a pathogen-associated antigen accreted at the focus of infection, the antibody conjugate further comprising a bound diagnostic or therapeutic agent for detecting, imaging or treating the infection. Polyspecific composite conjugates enhance the efficacy of the method, which is especially useful for treating infections that are refractory towards systemic chemotherapy.